Study aimed at evaluating the potential activity of alpha-lactalbumin (ALAC) in two experimental models of epilepsy in mice. Most striking result on audiogenic mice: after 3 weeks of treatment, seizure control continues for at least one month after its suspension.
Serplus (ALAC-based supplement) increases the convulsive threshold and acts on epileptogenesis. Since there is genetic damage, increasing the threshold increases the ability to defend against genetic damage.
Year: 2012
Nationality: Italy
Download the document